Compare Adaptive Biotechnologies Corp (ADPT) vs Broadcom Inc (AVGO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Broadcom Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.9 (market cap $3.33B), while Broadcom Inc trades at $394.35 (market cap $1.76T). The key difference: Broadcom Inc is far larger — about 528.5× Adaptive Biotechnologies Corp's market cap, and Broadcom Inc pays a 0.7% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AVGO | |
|---|---|---|
Market Cap | $3.33B | $1.76T |
Sector | Health | Technology |
52-Week High | $22.37 | $481.57 |
52-Week Low | $10.24 | $271.80 |
Enterprise Value | $3.19B | $1.81T |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Broadcom (AVGO) trades at $370.78, up 2.87% today but remains in a bearish technical trend, 25% below its 52-week high. The company demonstrates strong fundamentals with Q1 2026 EPS beating estimates at $2.44 and robust revenue growth from $51.6B in 2024 to $63.9B in 2025. Recent news highlights a strategic partnership extension with Apple through 2031 for custom AI chips, providing long-term revenue visibility amid a challenging market environment for semiconductor stocks.
AVGO presents a compelling investment case with strong analyst support (88% buy ratings) and a $510.43 consensus price target representing 38% upside. However, elevated valuation multiples (P/E 62.21, P/S 24.17) and technical bearish signals warrant caution. The key opportunity lies in AVGO's AI semiconductor growth (143% YoY to $10.8B last quarter) while risks include market volatility and competitive pressures in the chip sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →
